Recent advances in the management of type 2 diabetes mellitus: A review

Postgraduate Medical Journal

Volumn 84, Issue 996, 2008, Pages 524-531

  Srinivasan, B T ^a,b   Jarvis, J ^a,c   Khunti, K ^b   Davies, M J ^b  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; BIPHASIC INSULIN; BUFORMIN; EXENDIN 4; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PHENFORMIN; PIOGLITAZONE; PLACEBO; REPAGLINIDE; RIMONABANT; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN;

ABDOMINAL OBESITY; ANXIETY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG CONTRAINDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FLATULENCE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; KIDNEY DISEASE; META ANALYSIS; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREATITIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WATER RETENTION; WEIGHT GAIN; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; PIPERIDINES; PYRAZOLES;

EID: 56749104677     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2008.067918     Document Type: Review

References (59)

1. Diabetes UK. Diabetes Prevalence 2007. http://www.diabetes.org.uk/ en/Professionals/Information_resources/Reports/Diabetes-prevalence-2007/ (Accessed 2 May 2008)
2. Diabetes UK. Diabetes: State of the Nations 2005; Progress made in delivering the national diabetes frameworks. 9435/1205/a. 2005.
3. Kennel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 1979;2:120-6.
4. UKPDS Group. UK Prospective Diabetes Study 6. Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. Diabetes Research 1990;13:1-11.
5. International Diabetes Federation. Diabetes atlas. Brussels: International Diabetes Federation, 2006.
6. Turner R, Cull C, Holman RR. United Kingdom Prospective Diabetes Study 17: a 9 year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996;124(1 Pt 2):136-45.
7. Turner RC, Holman RR, Stratton IM, et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
8. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005-12.
9. Wright A, Burden AC, Paisey RB, et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:330-6.
10. Bagg W, Plank LD, Gamble G, et al. The effects of intensive glycaemic control on body composition in patients with type 2 diabetes. Diabetes Obes Metab 2001;3:410-16.
11. Makimattila S, Nikkila K, Yki-Jarvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with type 11 diabetes mellitus. Diabetologia 1999;42:406-12.
12. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
13. Dormandy JA Charbonnel B, Eckland DK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactice Study (PROspective pioglitaAzone Clinical Trial In MacroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89.
14. Elrick H, Stimmler L, Hlad CJ, et al. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964;24:1076-82.
15. Creutzfeldt W. The enters-insular axis in type 2 diabetes - incretins as therapeutic agents. Exp Clin Endocrinol Diabetes 2001;109(S2):288-303.
16. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007;298:194-206.
17. Baggio LL, Drucker DJ. Therapeutic approaches to preserve islet mass in type 2 diabetes. Annu Rev Med 2006;57:265-81.
18. Buse JB, Klonoff DC, Nielsen LL, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 2007;29:139-53.
19. Barnett AH. Exenatide. Drugs Today (Barc) 2005;41:563-78.
20. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35.
21. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100.
22. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91.
23. Zinman B, Hoogwerf BJ, Duran GS, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. [erratum appears in Ann Intern Med 2007;146:896] [summary for patients in Ann Intern Med 2007;146:118]. Ann Intern Med 2007;146:477-85.
24. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559-69.
25. Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007;50:259-67.
26. Barnett AH BJJD. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulphonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007;29:2333-48.
27. Anon. Information for Healthcare Professionals Exenatide (marketed as Byetta). 2007.
28. Madsbad S, Schmitz O, Ranstam J, et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004;27:335-42.
29. Scottish Medicines Consortium. Exenatide, 5 or 10 micrograms, solution for injection, prefilled pen No (376/07). http://www.scottishmedicines. org.uk/smc/5376.html. (Accessed 1 June 2008)
30. National Institute for Health and Clinical Excellence. Type 2 diabetes: the management of type 2 diabetes, update of NICE clinical guidelines E, F, G and H. NICE Clinical Guideline 66. London: NICE, May 2008.
31. Elrishi MA, Khunti K, Jarvis J, et al. The dipeptidyl-peptidase-4 (DPP-4) inhibitors, a new class of oral therapy for patients with type 2 diabetes mellitus. Practical Diabetes International 2007;24:474-82.
32. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2007;49:2564-71.
33. Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-7.
34. Pi-Sunyer FX, Schweizer A, Mills D, et al. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Research Clinical Practice 2007;76:132-8.
35. Schweizer A, Couturier A, Foley JE, et al. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with type 2 diabetes. Diabet Med 2007;24:955-61.
36. Goldstein BJ, Feinglos MN, Lunceford JK, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-87.
37. Ahren B, Gomis R, Standl E, et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004;30:217-23.
38. Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30:890-5.
39. Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-43.
40. Garber A, Camisaca RP, Ehrsam E, et al. Vildagliptin added to metformin improves glycaemic control and may mitigate metformin-induced GI side effects in patients with type 2 diabetes (T2DM). Diabetes 2006;55(Suppl 1):A29:121-0R.
41. Garber AJ, Camisaca RP, Jauffret S, et al. Efficacy and tolerability of vidigliptin added to a sulfonylurea (SU) in patients with type 2 diabetes (T2DM). Diabetes 2007;56(Suppl 1):0501-P.
42. Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007;9:733-45.
43. Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194-205.
44. Rosenstock J, Baron MA, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. [erratum appears in Diabetes Care 2007;30:1330]. Diabetes Care 2007;30:217-23.
45. Rosenstock J, Brazg R, Andryuk PJ, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006;28:1556-68.
46. Fonseca V, Schweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007;50:1148-55.
47. Herman GA, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of single doses of sitagliptin, an inhibitor of dipeptidyl peptidase-IV, in healthy subjects. Clin Pharmacol Ther 2005;78:675-88.
48. Cote D, Marsicano G, Tschop M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipo-genesis. J Clin Invest 2003;112:423-31.
49. Di Marzo V, Matias I, et al. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005;8:585-9.
50. Wynne K, Stanley S, McGowan B, et al. Appetite control. J Endocrinol 2005;184:291-318.
51. Jbilo O, Ravinet-Trillou C, Arnone M, et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 2005;19:1567-9.
52. Rinaldi-Carmona M, Barth F, Heaulme M, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994;350:240-4.
53. Finer N, Pagotto U. The endocannabinoid system: a new therapeutic target for cardiovascular risk factor management. Br J Diabetes Vasc Dis 2005;5:121-4.
54. Pi-Sunyer FX, Aronne U, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295:761-75.
55. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-97.
56. Despres J-P, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-34.
57. Scheen AJ, Van Gaal LG, Despres JP, et al. Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies. Rev Med Suisse 2006;2:1916-23.
58. Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight-loss drug rimonobant: a meta-analysis of randomized trials. Lancet 2007;370:1706-13.
59. US Food and Drug Administration Advisory Committee. FDA briefing document: Zimulti (rimonabant) tablets, 20 mg. Rockville: FDA, 2007.